DBV to Present Data at the 2017 AAAAI Meeting Highlighting

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
211
DBV to Present Data at the 2017 AAAAI Meeting Highlighting the Therapeutic Potential of EPIT®
Press Release Montrouge, France, February 10, 2017

DBV to Present Data at the 2017 AAAAI Meeting Highlighting the Therapeutic Potential of EPIT ®

Eight abstracts, including detailed two-year follow-up data to the VIPES Phase IIb trial supporting the long-term efficacy and safety of Viaskin Peanut for the treatment of peanut allergy, will be presented during the meeting DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced that eight abstracts, seven of which will highlight data from the company's Viaskin technology platform, were accepted for oral and poster presentation at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Atlanta, Georgia, March 3-6, 2017. These abstracts became available on the AAAAI meeting website at 9:30 AM CT on February 10  http://annualmeeting.aaaai.org/ .

Detailed results from the OLFUS-VIPES trial, which followed patients for a total of 36 months, will be presented during the Late Breaking Oral Abstract Session on Sunday, March 5. Topline results from OLFUS-VIPES, which evaluated the long-term efficacy and safety of Viaskin Peanut for the treatment of peanut-allergic children, were previously announced in October 2016. Viaskin Peanut is the company's lead product candidate based on its proprietary EPIT platform, which aims to deliver biologically active compounds to the immune system through the skin, and is currently being evaluated in a global, pivotal Phase III program in peanut-allergic children 4 to 11 years of age.

"The long-term clinical data we are presenting at AAAAI provide further insight into the promise of Viaskin Peanut as a potential treatment option for peanut-allergic children," said Dr. Lucia Septién , Chief Medical Officer of DBV Technologies. "These detailed results, combined with pre-clinical data that will be presented at the meeting, also underscore the tremendous potential of EPIT to help address a wide range of unmet medical needs."

Additional abstracts to be presented at the meeting include two pre-clinical studies, which tested the therapeutic potential of EPIT in type 1 diabetes and in the vaccination against respiratory syncytial virus (RSV). Selected abstracts of interest: Peanut Allergy Data

  • "Efficacy and Safety of Long-Term Epicutaneous Immunotherapy (EPIT) Treatment of Peanut Allergy with Viaskin® Peanut: Results of the Two-Year Extension of the VIPES Phase IIb Clinical Trial" will be presented by Dr. Wayne G. Shreffler, Division of Allergy and Immunology, Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School.
    • Oral Presentation
    • Session Number: 3611
    • Poster Number: L7
    • Session Title:  Late Breaking Oral Abstract Session: Clinical/Translational Science
    • Date/Time: Sunday, March 5 / 2:15 PM to 2:30 PM

FARRP ( Food Allergy Research & Resource Program ) Data

  • "Increasing Clinical Peanut Thresholds Through Immunotherapy: Quantitative Assessment of the Safety Benefits Associated with Achieving a 300 or 1000 mg Peanut Protein Threshold" will be presented by Dr. Joseph L. Baumert, Food Allergy Research and Resource Program, University of Nebraska-Lincoln.
    • Oral Presentation
    • Session Number: 3604
    • Poster Number: 561
    • Session Title:  Immunotherapy for Food Allergy
    • Date/Time: Sunday, March 5 / 2:45 PM to 3:00 PM

RSV Data

  • "Preclinical evaluation of a novel non-invasive epicutaneous vaccine against respiratory syncytial virus" will be presented by Dr. Pierre-Louis Hervé, DBV Technologies.
    • Session Number: 3802
    • Poster Number: 589
    • Session Title:  Immunotherapy: How to Reprogram the Immune System
    • Date/Time: Sunday, March 5 / 4:45 PM to 6:15 PM

Type 1 Diabetes Data

  • "EPIT decreases T1D incidence in sensitized non obese diabetic mice: a likely bystander effect of EPIT-induced Tregs" will be presented by Dr. Benjamin Pelletier, DBV Technologies.
    • Poster Session
    • Session Number: 2203
    • Poster Number: 52
    • Session Title:  Immune Modulation
    • Date/Time: Saturday, March 4 / 9:45 AM to 10:45 AM

EPIT Mechanism of Action Research        

  • "Treatment of eosinophilic gastritis by Epicutaneous Immunotherapy (EPIT) in peanut allergic piglets" will be presented by Dr. Lucie Mondoulet, DBV Technologies.
    • Poster Session
    • Session Number: 2208
    • Poster Number: 153
    • Session Title:  Eosinophilic Gastrointestinal Disorders and Non-IgE Mediated Food Allergy
    • Date/Time: Saturday, March 4 / 9:45 AM to 10:45 AM  
  • "Allergen Capture by DCs during Epicutaneous Immunotherapy is Enhanced by Modulating the Dose and the Surface Area of the Patch" will be presented by Dr. Sophie Wavrin, DBV Technologies.
    • Poster Session
    • Session Number: 4210
    • Poster Number: 806
    • Session Title:  Allergen Extracts and Other Forms of Immunotherapy
    • Date/Time: Monday, March 6 / 9:45 AM to 10:45 AM  
  • "Crucial Role of Langerhans Cells in Allergen Uptake and Regulatory T Cell Induction in Epicutaneous Immunotherapy" will be presented by Dr. Vincent Dioszeghy, DBV Technologies.
    • Poster Session
    • Session Number: 4210
    • Poster Number: 805
    • Session Title:  Allergen Extracts and Other Forms of Immunotherapy
    • Date/Time: Monday, March 6 / 9:45 AM to 10:45 AM  
  • "Foxp3+ CD62L+ Tregs induced by EPIT have the potency to suppress effector T cells proliferation in specific and bystander conditions" will be presented by Dr. Benjamin Pelletier, DBV Technologies.
    • Session Number: 4210
    • Poster Number: 801
    • Session Title:  Allergen Extracts and Other Forms of Immunotherapy
    • Date/Time: Monday, March 6 / 9:45 AM to 10:45 AM

Full data will be shared following embargo lift; at the time the studies are presented. All abstracts are available online at http://annualmeeting.aaaai.org/ , and will also be published in a supplement to the February Journal of Allergy and Clinical Immunology (JACI ) at http://www.jacionline.org/ .

About the PEPITES Study The Peanut EPIT Efficacy and Safety Study (PEPITES) is a global, pivotal, double-blinded, placebo-controlled Phase III trial designed to evaluate the safety and efficacy of Viaskin Peanut 250 mcg in children ages four to 11 years. During PEPITES, patients' response will be assessed using a double-blind, placebo controlled food challenge (DBPCFC). Patients are randomized 2:1 to receive either Viaskin Peanut 250 mcg or placebo for 12 months. The primary endpoint is based on a responder analysis after 12 months of treatment with Viaskin Peanut 250 µg. For patients with a baseline peanut protein eliciting dose (ED) equal to or less than 10 mg, a responder is defined as a patient with a peanut protein ED equal to or greater than 300 mg of peanut protein after 12 months of treatment. For subjects with a baseline ED greater than 10 mg, a responder is defined as a patient with a peanut protein ED equal to or greater than 1,000 mg of peanut protein after 12 months of treatment. As a secondary efficacy endpoint, Cumulative Reactive Dose (CRD), will also be used in PEPITES to establish the total quantity of peanut protein that triggers patient reactions at month 12 of active treatment versus placebo. Serological markers will also be measured at baseline, 3, 6, and 12 months in order to characterize the immunological changes in patients. Following the completion of PEPITES, all patients are eligible to rollover into PEOPLE, a long-term, open-label extension study of Viaskin Peanut 250 µg. In the PEOPLE study, patients who were randomized to active treatment during PEPITES will receive Viaskin Peanut 250 mcg for two additional years; patients who were previously receiving placebo during PEPITES will be treated with Viaskin Peanut 250 mcg for three years. Patients enrolling in the PEOPLE study will remain blinded to their respective treatment group in PEPITES until the PEPITES study results become publicly available.

About the REALISE Study REALISE is a multicenter, randomized, double-blind, placebo-controlled Phase III study designed to assess the use of Viaskin Peanut 250 mcg in routine medical practice and generate safety data after six months of blinded treatment in patients four to 11 years of age. At the six-month time point, patients in both the placebo and active arms will be able to opt into an open-label portion of the study, which will continue monitoring patients for a total of 36 months of active treatment. Exploratory criteria will also include scores from subjects' Food Allergy Quality of Life Questionnaire (FAQLQ) and the Food Allergy Independent Measure (FAIM), as well as the evolution of peanut-specific serological markers over time. The study is expected to be conducted in approximately 30 to 40 centers in North America. No oral food challenges are required in REALISE. Patients in the study will be selected based on a well-documented medical history of IgE-mediated reactions to peanut, including children with a history of severe anaphylaxis, as well as analyses of peanut-specific immunological markers. During the first six months of trial, patients will be randomized 3:1 active versus placebo. Key assessments of safety parameters will include treatment-emergent adverse events observed in both the placebo and active treatment groups after the initial 6 months, which will continue to be monitored during the open-label portion of the study. DBV intends to enroll approximately 335 subjects in REALISE.

About the OLFUS-VIPES Study OLFUS-VIPES (Open-Label Follow-Up Study-Viaskin Peanut's Efficacy and Safety), or OLFUS, enrolled 171 subjects who had previously received either placebo or one of three 12-month dose regimens administered during VIPES. During the first year of OLFUS, patients were to receive a daily application of Viaskin Peanut 50 µg or Viaskin Peanut 100 µg or Viaskin Peanut 250 µg for 12 months. According to a study protocol change implemented in March 2014, all patients were switched to receive Viaskin Peanut 250 mcg during OLFUS. All patients in OLFUS maintained a peanut-free diet during the study. Baseline response levels in OLFUS were based on the results of the last double-blind, placebo controlled food challenge (DBPCFC) in VIPES, and adjusted by the number of patients enrolling in OLFUS. Responders in the OLFUS trial were defined as subjects with a peanut protein eliciting dose equal to or greater than 1,000 mg peanut protein or with a greater than 10-fold increase of the eliciting dose compared to their baseline eliciting dose observed in the VIPES study. Patients enrolled in OLFUS who received placebo in VIPES were analyzed separately from subjects who initially received Viaskin Peanut. At month 24 in OLFUS, patients who were unresponsive to a cumulative dose above 1,440 mg were eligible to discontinue study drug for two months while maintaining a peanut-free diet. Patients who opted to enter into this additional period performed a DBPCFC at month-26 to assess durability of response.

About DBV Technologies  DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

Forward Looking Statements This press release contains forward-looking statements, including statements regarding the potential safety and efficacy of Viaskin Peanut and statements reflecting management's expectations for clinical development of our product candidates and the commercial potential of our product candidates. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2015 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise. 

DBV Technologies Contact Susanna Mesa Senior Vice President, Strategy +1 212-271-0861 susanna.mesa@dbv-technologies.com

Media Contact Andrea Fassacesia, Weber Shandwick +1 212-445-8144 afassacesia@webershandwick.com

Media Contact Europe Caroline Carmagnol, Alize RP, Relations Presse +33 (0)6 64 18 99 59  caroline@alizerp.com

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...458a8918ae

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 17

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 119

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 36

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 183

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 78

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 98

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 0

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 39

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading

Top 5 Most Recently Viewed Articles

Valory Resources Enhances Leadership with Major Investment

Updated Category News Views 370

Valory Resources Secures Strategic Investment Valory Resources Inc. has made headlines by securing a strategic investment worth CAD$8.5 million from notable Canadian business figures W. Brett Wilson and Russell Wilson. This investment showcases a strong endorsement of Valory's vision, particularly regarding its steelmaking coal mining projects. New Additions to the Board...

Continue Reading
Dr. Melonie Boone Revives Boone Management Group for Modern Needs

Updated Category News Views 476

Dr. Melonie Boone Unveils a New Chapter for Boone Management Group Dr. Melonie Boone, an experienced business psychologist and former COO, has announced the exciting relaunch of Boone Management Group (BMG). This management consulting firm is set to redefine the landscape of organizational health and performance through a cutting-edge, psychology-oriented approach. With a...

Continue Reading
CPSC Addresses Recent Product Recalls for Consumer Safety

Updated Category News Views 229

Understanding Recent Product Recalls The U.S. Consumer Product Safety Commission (CPSC) has take significant steps to protect consumers from unsafe products by announcing multiple recalls. These actions aim to provide vital information that can prevent potential hazards in homes across the nation. Highlighted Product Recalls Among the recalls is a concerning announcement...

Continue Reading
Iceland Treasury Unveils New Bond Series for Market

Updated Category News Views 288

Iceland Treasury Announces New Bond Series The Icelandic Treasury has made an important announcement regarding the issuance of nine new government bond series. This move is linked to the settlement of the ÍL Fund, previously known as the Housing Financing Fund. Investors and financial analysts will want to pay close attention to these developments as they can have...

Continue Reading
Hormel Foods’ Significant Contribution to Wildfire Relief Efforts

Updated Category News Views 241

Hormel Foods’ Commitment to Community Support In response to the devastations caused by wildfires, Hormel Foods Corporation (NYSE: HRL) is stepping up to lend a hand. The company has made a pledge to support disaster relief efforts as California faces ongoing challenges brought on by these fires. This initiative underscores Hormel Foods' commitment to the well-being of...

Continue Reading